

21 NCAC 36 .0817 is adopted under temporary procedures with changes as follows:

21 NCAC 36 .0817 COVID-19 DRUG PRESERVATION RULE

(a) The following drugs are “Restricted Drugs” as that term is used in this Rule:

- (1) Hydroxychloroquine;
- (2) Chloroquine;
- (3) Lopinavir-ritonavir;
- (4) Ribavirin;
- (5) Oseltamivir;
- (6) Darunavir; and
- (7) Azithromycin.

(b) A nurse practitioner shall prescribe a Restricted Drug only if that prescription bears a written diagnosis from the prescriber consistent with the evidence of its use.

(c) When a patient has been diagnosed with COVID-19, any prescription of a Restricted Drug for the treatment of COVID-19 shall:

- (1) Indicate on the prescription that the patient has been diagnosed with COVID-19;
- (2) Be limited to no more than a ~~fourteen-day~~ 14-day supply; and
- (3) Not be refilled, unless a new prescription is issued in conformance with this Rule, including not being refilled through an emergency prescription ~~refill~~ refill.

(d) A nurse practitioner shall not prescribe a Restricted Drug for the prevention of, or in anticipation of, the contraction of COVID-19 by someone who has not yet been diagnosed.

(e) A prescription for a Restricted Drug may be transmitted orally only if all information required by this Rule is provided to the pharmacy by the nurse ~~[practitioner,]~~ practitioner, or the nurse practitioner’s agent, and that information is recorded in writing in accordance with 21 NCAC 46 .1819(e). ~~by the pharmacy, along with the identity of the nurse practitioner transmitting the prescription.~~

(f) This Rule does not affect orders for administration to inpatients of health care facilities.

(g) This Rule does not apply to prescriptions for a Restricted Drug for a patient previously established on that particular Restricted Drug on or before March 10, 2020.

History Note: Authority G.S. 90-171.23; ~~[90-171.49,]~~ 90-5.1; ~~[90-8.2; 90-12.5]~~ 90-8.2.

Eff. June 26, 2020